Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Medical Devices Need Follow Up After U.S. Approval, Senators Say

The DePuy ASR XL Acetabular System was recalled in 2010 by the company. Source: Johnson & Johnson
The DePuy ASR XL Acetabular System was recalled in 2010 by the company. Source: Johnson & Johnson

Dec. 16 (Bloomberg) -- U.S. regulators would gain greater authority to track the use of devices, such as hip implants from Johnson & Johnson and vaginal meshes made by Boston Scientific Corp., that have sparked thousands of patient lawsuits, under a bill introduced in the Senate.

Under the legislation, the Food and Drug Administration could order companies to conduct safety studies of devices after they’re approved and could grant conditional approvals pending the result of ongoing trials. That would strengthen rules for products approved through the so-called 510(k) system, which now requires companies only to show their devices are similar to those already on the market.

The procedure was used to clear hip implants recalled in 2010 by J&J, the world’s largest maker of medical devices, and vaginal meshes that spurred an FDA warning earlier this year. In July, the Institute of Medicine, a U.S. advisory group, urged the FDA to replace 510(k), saying it didn’t ensure safety.

“Faulty medical devices, especially those implanted in the body, can have disastrous health impacts on patients,” said U.S. Senator Herb Kohl, one of the bill’s three sponsors, in a statement. “This legislation will help ensure that FDA can act quickly and decisively when there’s a problem and that the drive toward getting new technologies to market won’t come at the risk of patient safety.”

The legislation was introduced by Kohl, a Wisconsin Democrat, Senator Charles Grassley, a Republican of Iowa, and Senator Richard Blumenthal, a Connecticut Democrat.

Letters to Companies

The senators have sent letters to five companies that recalled faulty medical devices, including New Brunswick, New Jersey-based J&J, Minneapolis, Minnesota-based Medtronic Inc. and Murray Hill, New Jersey-based CR Bard Inc., requesting information about how the manufacturers conduct post-market surveillance and manage recalls.

Jeffrey Shuren, director of the FDA’s device-review center, declined to comment on the legislation, saying he hadn’t yet seen the bill.

The agency is limited in its current authority to order post-approval reviews, said Christy Foreman, director of the FDA’s Office of Device Evaluation. Studies like those it required earlier this year by J&J and other hip-implant makers can’t last longer than three years, Foreman said. And the agency can’t mandate long-term studies as part of 510(k) approvals, she said in an interview.

Lobby Response

The Advanced Medical Technology Association, the device industry lobby group in Washington, opposes expanding FDA’s post-market authority because it is unnecessary, said Janet Trunzo, executive vice president for technology and regulatory affairs at the group.

“It is important for the American public to realize that the medical technology industry has a well-documented safety record,” Trunzo said in a statement. “Several recent studies have shown that for the vast majority of products cleared by the FDA, less than 0.5 percent are involved in a serious recall.”

The legislation should be included in reauthorization of the FDA’s medical device user fee program that helps fund the review process, Grassley said. The program must be reauthorized by October. While consumer advocates have criticized the FDA as too lax, the agency has also come under fire this year from device makers who say reviews take too long.

Shuren, in a meeting yesterday with investors in New York, said the FDA had heard the complaints and is making the process faster and more consistent.

The percentage of 510(k) applications granted a final decision has risen to 78 percent this year, after four years of declines. The percentage of initial reviews in which the FDA has sought more information may fall for the first time since 2002, he said. The meeting was held by Wells Fargo & Co.

“Our mission is to protect the public health,” Shuren said. “But it’s also to promote public health by promoting innovation. There’s this misperception out there that the two are inconsistent but we think they are very compatible.”

To contact the reporter on this story: Anna Edney in Washington at aedney@bloomberg.net; Alex Nussbaum in New York at anussbaum1@bloomberg.net.

To contact the editors responsible for this story: Reg Gale at rgale5@bloomberg.net; Adriel Bettelheim at abettelheim@bloomberg.net.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.